Stock market week in review, Saturday, 14 November 2026

The week in review

The close-of-day read for 13 November 2026 is neutral, unchanged from the prior session. No risk-off trigger is met, and breadth is short of the line a risk-on call needs.

The S&P 500 (via SPY) closed 3.1% above its 200-day average. Breadth stands at 56.9%, with 568 of 998 stocks above their own 50-day average. That is healthy but unconfirmed. The VIX, Cboe's index of the S&P 500's expected volatility over the next 30 days, closed at 19.3. That sits inside its elevated band of 18 to 28.

The call stays neutral while no risk-off trigger is met. A risk-on call needs breadth above 60% (now 56.9%). The call turns risk-off if the S&P 500 closes more than 2% below its 200-day average (now +3.1%), if breadth falls under 40% (now 56.9%), or if the VIX rises above 28 (now 19.3).

Treasury yields made the week's largest moves. A basis point (bp) is one hundredth of a percentage point. The 2-year yield rose 35 bp week over week to 4.86%, and the 10-year rose 24 bp to 5.10%, both as of 12 November 2026. Short-dated yields rose faster. The 10-year less 2-year spread narrowed 8 bp week over week to 0.27% as of 13 November 2026.

The increase came through real yields, the return after inflation. The 10-year breakeven inflation rate moved 1 bp week over week to 2.24% as of 13 November 2026. The real 10-year rate rose 23 bp to 2.86% as of 12 November 2026. The likelier reading is that bond buyers demanded a higher return after inflation, not that they priced more inflation. Both Treasury yields sit above the effective federal funds rate of 3.88% on 12 November 2026.

Credit markets did not show strain. The high-yield spread is the extra yield lower-rated corporate bonds pay over Treasuries. It narrowed 22 bp week over week to 3.20% as of 12 November 2026.

Labor data point to a firm job market. Initial jobless claims were 200K in the week ending 7 November 2026, up 9K week over week. Unemployment was 4.1% in October 2026, and nonfarm payrolls stood at 159.3M. Housing starts ran at 1,221K in September 2026. Rates, credit, labor and housing are context for the reading. The regime rules do not use them to set the call.

Themes in motion

Thirteen themes were given a stage in the latest theme run, on the 13 November 2026 close: 2 accelerating, 8 maturing, 3 saturated.

Rare disease and gene therapy, and travel and leisure, are accelerating. Buying is spreading across each group, and the news driving it is new.

These themes are maturing: mergers and acquisitions and special situations; artificial intelligence (AI) enterprise software; consumer brands and retail; medtech, diagnostics and life-science tools; oncology and immunology; defense and aerospace; managed care and health services; and cyclical industrials. Their stories are widely known and their stocks still hold up, but the news repeats rather than adds.

Fintech, payments and credit; ad tech and digital advertising; and solar and clean energy are saturated. Their stories are largely in the price, and few new buyers are left.

The stages come from a single run on the 13 November 2026 close. They show where each theme stands now. They do not show how far a theme moved during the week.

Rated highest this week

Two research notes are rated high conviction: Advantest Corporation (ATEYY) and Azenta, Inc. (AZTA).

• Advantest Corporation (ATEYY). Advantest sells test equipment for AI chips. Demand for that equipment depends on how many chips its customers make, and those volumes are still rising. TSMC reported on 10 November 2026 that its October revenue rose 59.7% from a year earlier. Wrong if: a weekly close below $150.
• Azenta, Inc. (AZTA). The research holds that Azenta is more likely than not to beat the S&P 500 over three months. The basis is its fiscal 2027 plan, issued 10 November 2026, which lays out 3% to 5% organic growth and a wider margin. Wrong if: a daily close below $39.16.

The week ahead

The coming week's dated company catalysts fall on Sunday, 15 November, and Monday, 16 November. They include two quarterly reports, two debt maturities, a clinical readout, insurer coverage changes and filing deadlines.

Sunday, 15 November

• Amylyx Pharmaceuticals (AMLX): full LUCIDITY results are presented as a late-breaking oral session at ObesityWeek 2026 in Washington, D.C., at 8:30 a.m. Eastern time. The complete data set will either support the program in detail or weaken it.
• Diana Shipping (DSX): the minimum term ends on the P. S. Palios Capesize charter with Glencore, which pays $25,200 a day gross. The maximum term runs to 15 January 2027. After the minimum date that rate is no longer locked in, and the vessel's next charter rate sets its earnings.
• Freenome (FRNM) and Guardant Health (GH): Carelon's revised liquid-biopsy guideline takes effect, and so does Carelon's coverage of Shield. The changes put coverage in force on paper. Test volumes in later quarterly reports will show whether it turns into revenue.
• Rising Dragon Acquisition Corp. (RDAC): its current deadline to complete a business combination arrives. Another monthly extension deposit is required to continue. A deposit keeps the deal timeline alive. Without one, the company is past its deadline.
• Unity Software (U): its 2026 convertible notes mature, with $557.7 million of principal outstanding at 30 September 2026. The settlement shows how the company retires that debt.
• Veritone (VERI): its 1.75% convertible senior notes mature, with $45.58 million of principal. Repayment in full clears the maturity. A shortfall would put repayment in doubt.

Monday, 16 November

• Baidu (BIDU): third-quarter 2026 results come before the US open, with a call at 7:30 a.m. Eastern time. The report puts the quarter's revenue and profit on the public filing.
• Ballard Power Systems (BLDP): third-quarter 2026 results and a conference call at 8:00 a.m. Pacific time. The report shows the quarter's revenue and losses.
• Anavex Life Sciences (AVXL): a poster at the Clinical Trials on Alzheimer's Disease conference in Boston, which runs to 19 November 2026. A poster adds evidence only if it carries new data.
• Aquestive Therapeutics (AQST), Bicara Therapeutics (BCAX) and Assembly Biosciences (ASMB): Aquestive presents at the Jefferies Global Healthcare Conference at 10:00 a.m. GMT, followed by investor meetings. Bicara presents at the Jefferies investor conference. Assembly appears at the UBS Global Biopharma Conference. These appearances settle nothing unless they bring new data or guidance.
• American Resources (AREC): this is Nasdaq's deadline for the company's overdue quarterly Form 10-Q reports for the March and June quarters of 2026. Filing both reports puts the company back in line with the exchange. Missing the deadline deepens its listing problem.
• Beam Global (BEEM): this is the company's own stated deadline to file its third-quarter Form 10-Q, on or before the date. An on-time filing confirms its reporting is current. A miss would add a late-filing problem.